Senior research engineer in gene editing with focus on metabolic disorders
Sort on published: 2019-01-18
Uppsala University is a comprehensive research-intensive university with a strong international standing. Our mission is to pursue top-quality research and education and to interact constructively with society. Our most important assets are all the individuals whose curiosity and dedication make Uppsala University one of Sweden’s most exciting workplaces. Uppsala University has 42,000 students, 7,000 employees and a turnover of SEK 6.7 billion.
Department of Medical Sciences, Endocrinology
Area of responsibilities/description of the work
The Department of Medical Sciences, Uppsala University, has launched a strategic program on gene editing as a research tool and potential future treatment modality. The program focuses on metabolic disorders including type 1 and type 2 diabetes, obesity, bone diseases and inborn errors of metabolism. We primarily use human primary cells and cell lines; stem cells, immune cells as well as adipose and bone precursor cells. The studies will be run in collaboration with other research groups at Uppsala University as well as with national and international networks.
We have identified several novel molecular markers, mechanisms and/or drug targets of relevance for type 1 and type 2 diabetes, obesity as well as inherited bone and metabolic disorders. In the project, we plan to employ the CRISPR/Cas-9 technique to assess their role in vitro with respect to phenotypic effects on differentiation, metabolism and other functions of human cells. In parallel, in vivo studies are planned for investigations of whole-body effects in animal models, and clinical investigations will be performed in patients and control subjects.
The techniques employed will include cell culturing and CRISPR/Cas-9 techniques for gene knockdown in human cells to study the impact of novel molecular mediators in disease pathways.
The work duties include independent in-vitro experimental work, in particular gene editing, cell culturing and phenotyping. Development and establishment of methodology in these areas.
To qualify, the applicants should preferably hold a doctoral degree. The candidate is expected to have at least 2 years of experience in advanced molecular biology techniques including gene silencing. Excellent skills in spoken and written English. Experience of translational research in metabolic/endocrine disorders is desirable. In addition, documented skills with respect to scientific independence, leadership and collaboration are of importance.
Salary: Individual salary.
Starting date: As soon as possible.
Form of employment Time-limited employment for 2 years.
Extent of employment: 100%
Contact persons For further information regarding the position; please contact Professor Jan Eriksson (firstname.lastname@example.org, +46 018 6114419), Professor Andreas Kindmark (email@example.com), Professor Per-Ola Carlsson (firstname.lastname@example.org) or HR-generalist Gabriella Widerberg, email@example.com.
The following documents must be submitted with your application and be written in English:
1. A full CV, academic title, current position, previous academic appointments, scientific skills, academic distinctions and committee work. If applicable, title of thesis and date of public defense.
2. A full publication list.
3. A brief statement (maximum 1 page) of research interests and goals.
4. Transcripts of diplomas from relevant previous education.
5. Names and contact information of three reference persons.
Please send your application, marked with reference number UFV-PA 2019/84, to reach us no later than February 18, 2019.
Please do not send offers of recruitment or advertising services. Applications must be submitted as described in this advertisement.
Placement: Department of Medical Sciences
Type of employment: Full time , Temporary position longer than 6 months
Pay: Fast lön
Number of positions: 1
Working hours: 100%
County: Uppsala län
Number of reference: UFV-PA 2019/84
Last application date: 2019-02-18